Loading…
Celcuity Inc., a clinical-stage biotechnology company, focuses on the development of targeted therapies for the treatment of various solid tumors in the United States. The company's lead drug candidate includes Gedatolisib, which selectively targets various Class I isoforms of phosphatidylinositol-3-kinase (PI3K) and the two mechanistic targets of rapamycin (mTOR) sub-complexes, mTORC1 and mTORC2 to treat patients with hormone receptor positive (HR+), human epidermal growth factor receptor 2 negative (HER2-) or HR+/HER2-, advanced or metastatic breast cancer (ABC), and patients with metastatic castration resistant prostate cancer (mCRPC). The company had a license agreement with Pfizer Inc. for the development and commercialization rights to Gedatolisib. Celcuity Inc. was incorporated in 2011 and is based in Minneapolis, Minnesota.
5-year financial trends. Figures in USD millions.
Latest fiscal year: 2025
Year-by-year revenue, profitability, and cash flow (USD millions, last 10 years)
| Year | Revenue | EBITDA | Net Profit | FCF | ROE | Rev Growth 1Y | NP Growth 1Y |
|---|---|---|---|---|---|---|---|
| 2025 | $0M | $-160M | $-177M | $-154M | -176.1% | - | 58.4% |
| 2024 | $0M | $-101M | $-112M | $-84M | -96.7% | - | 75.3% |
| 2023 | $0M | $-58M | $-64M | $-54M | -45.6% | - | 58.0% |
| 2022 | $0M | $-38M | $-40M | $-36M | -30.2% | - | - |
| 2021 | - | - | - | - | - |
Income statement, balance sheet, and cash flow as reported
Consolidated Figures in USD Millions.
| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Total Revenue | - | 0 | 0 | 0 | 0 |
| Operating Revenue | - | 0 | 0 | 0 | 0 |
| Operating Expense | - | 39.39 | 66.23 | 113.27 | 172.19 |
| Research And Development | - | 35.29 | 60.59 | 104.20 | 145 |
| Selling General And Administration | - | 4.10 | 5.64 | 9.06 | 27.20 |
| Total Expenses | - | 39.39 | 66.23 | 113.27 | 172.19 |
| Operating Income | - | -39.39 | -66.23 | -113.27 | -172.19 |
| Total Operating Income As Reported | - | -39.39 | -66.23 | -113.27 | -172.19 |
| EBITDA | - | -38.05 | -58.31 | -101.37 | -159.73 |
| Normalized EBITDA | - | -38.05 | -58.31 | -101.37 | -159.73 |
| EBIT | - | -38.26 | -58.45 | -101.50 | -159.89 |
| Interest Income | - | 1.13 | 7.78 | 11.77 | 12.30 |
| Interest Expense | - | 2.11 | 5.33 | 10.28 | 17.15 |
| Net Interest Income | - | -0.98 | 2.45 | 1.49 | -4.85 |
| Other Income Expense | 0 | - | - | - | - |
| Interest Income Non Operating | - | 1.13 | 7.78 | 11.77 | 12.30 |
| Interest Expense Non Operating | - | 2.11 | 5.33 | 10.28 | 17.15 |
| Net Non Operating Interest Income Expense | - | -0.98 | 2.45 | 1.49 | -4.85 |
| Pretax Income | - | -40.37 | -63.78 | -111.78 | -177.04 |
| Tax Provision | - | 0 | 0 | 0 | 0 |
| Tax Rate For Calcs | - | 0 | 0 | 0 | 0 |
| Tax Effect Of Unusual Items | - | 0 | 0 | 0 | 0 |
| Net Income Continuous Operations | - | -40.37 | -63.78 | -111.78 | -177.04 |
| Net Income From Continuing And Discontinued Operation | - | -40.37 | -63.78 | -111.78 | -177.04 |
| Net Income From Continuing Operation Net Minority Interest | - | -40.37 | -63.78 | -111.78 | -177.04 |
| Net Income | - | -40.37 | -63.78 | -111.78 | -177.04 |
| Net Income Common Stockholders | - | -40.37 | -63.78 | -111.78 | -177.04 |
| Net Income Including Noncontrolling Interests | - | -40.37 | -63.78 | -111.78 | -177.04 |
| Normalized Income | - | -40.37 | -63.78 | -111.78 | -177.04 |
| Diluted NI Availto Com Stockholders | - | -40.37 | -63.78 | -111.78 | -177.04 |
| Basic Average Shares | - | 15.42 | 23.68 | 39.45 | 46.76 |
| Diluted Average Shares | - | 15.42 | 23.68 | 39.45 | 46.76 |
| Reconciled Depreciation | - | 0.21 | 0.14 | 0.13 | 0.17 |
| Total Unusual Items | 0 | 0 | - | - | - |
| Total Unusual Items Excluding Goodwill | 0 | 0 | - | - | - |
| Special Income Charges | 0 | 0 | - | - | - |
| General And Administrative Expense | - | 4.10 | 5.64 | 9.06 | 27.20 |
| Other Gand A | - | 4.10 | 5.64 | 9.06 | 27.20 |
| Gain On Sale Of Ppe | 0 | 0 | - | - | - |
Healthcare sector peers, ranked by market cap
| Company | Ticker | Market Cap | P/E | P/B | ROE | EV/EBITDA |
|---|---|---|---|---|---|---|
| Celcuity Inc.this co. | CELC | $4.5B | -25.47 | 44.85 | -176.1% | -29.21 |
| CG Oncology, Inc. | CGON | $4.9B | -30.73 | 6.57 | -21.4% | -26.00 |
| Twist Bioscience Corporation | TWST | $4.6B | -59.27 | 9.73 | -16.4% | -40.36 |
| Dianthus Therapeutics, Inc. | DNTH | $4.6B | -28.33 | 9.32 | -32.9% | -25.63 |
| Amicus Therapeutics, Inc. | FOLD | $4.5B | -167.83 |
| - |
| - |
| 16.59 |
| -9.9% |
| 88.80 |
| Travere Therapeutics, Inc. | TVTX | $4.3B | -168.11 | 37.40 | -22.2% | 203.89 |
| 10x Genomics, Inc. | TXG | $4.3B | -97.67 | 5.34 | -5.5% | 988.34 |
| Erasca, Inc. | ERAS | $4.1B | -33.13 | 12.69 | -38.3% | -31.96 |
| LivaNova PLC | LIVN | $4.0B | -16.70 | 3.37 | -20.2% | -34.40 |
| Peer Median | - | -46.20 | 9.53 | -20.8% | -25.81 | |